Juvenile idiopathic arthritis
rheumatology · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic arthritis beginning before age 16 and persisting at least 6 weeks, with no other identified cause. Several subtypes exist; early diagnosis and treatment prevent joint damage, and uveitis screening protects sight.
Red flags
- Fever, weight loss, bone pain or cytopenias (exclude leukaemia before steroids)
- Features of macrophage activation syndrome in systemic JIA (high fever, cytopenias, high ferritin)
- Acutely hot, immobile joint with systemic upset (septic arthritis)
- Visual symptoms or detected uveitis
Assessment
Differential diagnosis
- Reactive/post-infectious arthritis
- Septic arthritis or osteomyelitis
- Lyme arthritis
- Leukaemia or bone tumour
- Systemic lupus or other connective tissue disease
- Henoch-Schonlein purpura / vasculitis
- Haemarthrosis or orthopaedic/mechanical cause
Investigations
- Clinical diagnosis of persistent arthritis after excluding other causes
- FBC, ESR/CRP, blood film (exclude malignancy)
- ANA (uveitis risk), rheumatoid factor, HLA-B27 as relevant to subtype
- Joint ultrasound/MRI to confirm synovitis
- Exclude infection (joint aspiration if septic arthritis possible)
- Slit-lamp ophthalmology screening for asymptomatic uveitis
Management
- Confirm persistent arthritis (>=6 weeks) and determine the number of joints and systemic features
- Exclude mimics, particularly infection and malignancy, before immunosuppression
- Arrange prompt slit-lamp examination to detect silent uveitis
- Refer to paediatric rheumatology for diagnosis and subtype classification
- Start NSAIDs and intra-articular corticosteroid injections for symptom control
- Introduce methotrexate early for persistent/polyarticular disease
- Escalate to biologic therapy for inadequate response or systemic disease
- Provide physiotherapy, occupational therapy and multidisciplinary support
- Maintain regular ophthalmology surveillance and monitor for medication toxicity
Drugs & doses
Naproxen ~10 mg/kg/day PO in divided doses (symptom control)
Intra-articular triamcinolone injections for oligoarticular disease (specialist)
Methotrexate 10-15 mg/m2 once weekly PO/SC with folic acid
Biologics (e.g. etanercept, adalimumab, tocilizumab) for refractory/systemic disease (specialist)
Disposition
Paediatric rheumatology management with ophthalmology surveillance; admit for systemic disease, suspected MAS, or septic arthritis exclusion.
Complications & pitfalls
- Joint damage, contractures and growth disturbance
- Chronic anterior uveitis with visual loss
- Macrophage activation syndrome (systemic JIA)
- Medication toxicity and growth/psychosocial effects
Exam pearls
- Always exclude leukaemia with blood film/counts before giving steroids to a child with joint pain
- ANA-positive young girls with oligoarthritis have the highest uveitis risk and need frequent screening
- Early methotrexate changes the disease course and limits damage
- Uveitis is often asymptomatic; regular slit-lamp screening is essential
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.